DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT04218656

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04218656
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04218656. Non-randomized; no masking; primary purpose treatment. Start 2020-06-08 (actual); primary completion 2021-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
Acronym
DUAL-PAD
Condition
Peripheral Artery Disease
Intervention (Drug)
Rivaroxaban 2.5 Mg Oral Tablet
Lead sponsor
Radboud University Medical Center (class: other)

Record details

Record id
cardio:ct-nct04218656
Content hash
8a9a43d5495735ad852aabb6efc422acb6e60758186315ee3d6933ac28e658a7